Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Salt Lake City, Utah, that focuses on revolutionizing drug discovery through the integration of advanced technologies such as artificial intelligence, automation, and bioinformatics. Founded in 2013, the company has developed a comprehensive drug discovery platform that includes various tools and software, such as ReChem for chemical compound design, ReScreen for managing complex experimental workflows, and RePredict for modeling drug relationships using machine learning. These innovations enable Recursion to generate extensive biological and chemical datasets, facilitating the exploration of foundational biology and accelerating the development of new therapeutic solutions. Through its unique approach, Recursion aims to significantly enhance patient outcomes and streamline the drug discovery process.

Michael Secora

CFO

4 past transactions

Exscientia

Acquisition in 2024
Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Cyclica

Acquisition in 2023
Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.

InVivo AI

Acquisition in 2023
InVivo AI, founded in 2017 and based in Montreal, Canada, specializes in utilizing artificial intelligence to enhance pharmaceutical research and development, particularly in the area of preclinical toxicology. The company aims to streamline the drug discovery process by implementing advanced AI methods for molecular representation and de novo design, which allows for the creation of novel chemical compounds that can address complex biological challenges. Through its innovative platform, InVivo AI is positioned to significantly improve the efficiency and effectiveness of drug design, paving the way for breakthroughs in pharmaceutical science.

Vium

Acquisition in 2020
Vium, Inc. is a biotechnology company focused on transforming preclinical research and enhancing animal welfare through the development of digital biomarkers. Fully accredited by AAALAC International, Vium has received commendation for its commitment to the principles of humane animal research. The company's platform, known as Digital Vivarium and Vium Cloud, integrates advanced technologies such as computer vision, artificial intelligence, and machine learning to non-invasively capture and analyze physiological metrics and behaviors. This innovative approach provides researchers across biotechnology, pharmaceutical, and academic sectors with accurate data that facilitates better decision-making regarding which compounds to advance to clinical trials. Founded in 2013 and headquartered in San Mateo, California, Vium aims to accelerate the preclinical drug discovery and development pipeline while ensuring ethical standards in research practices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.